SWITCH
What it tests: Target switching with conserved-payload novel antibody-drug conjugates (ADCs) in metastatic breast cancer following prior ADC therapy. Prospective, open-label phase 2 platform trial.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.